EXHIBIT 99.3

Contacts:
ATS Medical, Inc.
Michael Dale
President and CEO, 763-557-2224
Jack Judd
CFO, 763-557-2222

EVC Group
Douglas Sherk, 415-896-6820
Anne Bugge, 206-926-5220
Jennifer Beugelmans, 415-896-6820


FOR IMMEDIATE RELEASE


           ATS MEDICAL CLOSES ON SALE OF $13.1 MILLION OF COMMON STOCK


MINNEAPOLIS, June 28, 2004---ATS Medical, Inc. (Nasdaq: ATSI) today announced
the closing of the sale of approximately 3.7 million shares of common stock with
gross proceeds of $13.1 million. The Company issued no warrants in conjunction
with the sale. Adams, Harkness & Hill acted as the placement agent for the
financing.

The Company plans to use the proceeds for general working capital purposes and
to finance the manufacturing of the ATS Open Pivot(R) Valve and its components
in the Company's own facility. ATS also plans to continue to seek strategic
investments in additional products that will leverage its operating platform and
expand its presence in the cardiovascular surgery market.

"Ramping up manufacturing of the ATS Open Pivot Valve is a critical step to
achieving our goal of positive operating income and profitability" said Michael
Dale, ATS Chairman and CEO. "As our rapid growth depletes our existing finished
goods inventory, the proceeds from this placement will enable us to transition
to manufacturing our own products in-house, thereby realizing important cost
savings and improved gross margins. We plan to begin the transition during the
second half of 2004. In addition, some of the funds raised will be used to
accelerate completion and market introduction of the PARSUS blood filtration
technology for use in cardiac surgery procedures for which we recently acquired
exclusive worldwide rights. With this transaction completed, we believe we have
the financial resources in place to fund operations until we reach
profitability."

The securities sold have not been registered under the Securities Act of 1933,
as amended, and may not be offered or sold in the United States absent
registration or applicable exemption from registration. ATS Medical has agreed
to file, no later than 15




business days after the closing, a registration statement providing for the
resale of the common stock.

ABOUT ATS MEDICAL

ATS Medical, Inc., headquartered in Minneapolis, is a leading medical device
company specializing in mechanical heart valves, aortic graft prostheses and
related cardiovascular surgery accessories. ATS is a global company with product
sales in more than 40 countries. The ATS Open Pivot(R) Valve has been implanted
in over 85,000 patients and utilizes a unique pivot design that results in
better performance and a lower risk profile. The Company's website is
www.atsmedical.com.

SAFE HARBOR

All statements in this news release that are not statements of historical fact
are forward-looking statements. These statements are based on expectations and
assumptions as of the date of this press release and are subject to numerous
risks and uncertainties, which could cause actual results to differ materially
from those described in the forward-looking statements. The risks and
uncertainties include the ability of the Company and the investors to comply
with certain conditions to closing as set forth in the definitive agreements.
ATS Medical assumes no obligation to update these forward looking statements,
and does not intend to do so.

                                       ###